Results 1 to 10 of about 6,107 (224)

Adjunctive terlipressin versus placebo in the treatment of refractory septic shock: a randomized, placebo-controlled trial [PDF]

Crit Care
Terlipressin’s role as an adjunctive vasopressor in septic shock remains controversial. We aimed to evaluate the efficacy of terlipressin versus placebo as an additional vasopressor in refractory septic shock.
Surat Tongyoo, Chawanee Chayakul, Thipdhorn Aritajati, Tanya Tanyalakmara   +3 more
semanticscholar   +3 more sources

Terlipressin for Hepatorenal Syndrome in Patients With Early‐Stage Acute‐on‐Chronic Liver Failure [PDF]

Liver Int
Hepatorenal syndrome‐acute kidney injury (HRS‐AKI) is a life‐threatening complication of decompensated cirrhosis. The US Food and Drug Administration approved terlipressin use for HRS‐AKI based on the CONFIRM study, which demonstrated a significant ...
Don C. Rockey, Fredric Gordon, P. Thuluvath, David Victor, N. Kemmer, S. Cardoza, Khurram Jamil, R. Frederick   +7 more
semanticscholar   +3 more sources

Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome‐Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies [PDF]

Aliment Pharmacol Ther
Terlipressin is the FDA‐approved systemic vasoconstrictor therapy for hepatorenal syndrome‐acute kidney injury (HRS‐AKI)—a rapidly progressive renal failure occurring in patients with decompensated cirrhosis and ascites.
J. Bajaj, Paul Kwo, S. C. Pappas, Jacqueline G. O'Leary, Khurram Jamil, S. Cardoza, Florence Wong   +6 more
semanticscholar   +3 more sources

Effectiveness and safety evaluation of terlipressin in the treatment of intestinal paralysis in end-stage liver disease [PDF]

BMC Gastroenterology
Background and aims Intestinal paralysis is a common complication in end-stage liver disease (ESLD), our aim is to assess the effectiveness and safety of low-dose terlipressin for treating intestinal paralysis in ESLD.
Xia Wan, Hua Xu, Hu Li, Shan Zhong, Yu Lei, Huan Deng, Xiao Fu, Zhi Zhou   +7 more
doaj   +3 more sources

Safety and efficacy of continuous infusion terlipressin (BIV201): A phase 2 trial in patients with decompensated cirrhosis and refractory ascites [PDF]

Liver Transpl
Refractory ascites often requires therapeutic paracentesis, which is associated with potential risks and diminished quality of life. Terlipressin is a vasopressin analog that is indicated for i.v.
Jasmohan S. Bajaj, Ethan M. Weinberg, K. Rajender Reddy, Andrew P. Keaveny, Michael K. Porayko, David Koch, Paul J. Thuluvath, Douglas A. Simonetto, Paolo Angeli, Sujit Janardhan, Eric S. Orman, Jeffrey Zhang, S. W. Clausen, Elisa Dauphinée, Joseph Palumbo, Penelope Markham   +15 more
semanticscholar   +3 more sources

Hyponatraemia Induced by Terlipressin in Patients Diagnosed with Decompensated Liver Cirrhosis and Acute Variceal Bleeding [PDF]

Medicines
Background: Hyponatraemia is a rare but potentially life-threatening complication of terlipressin therapy. Case history: In the current case, a 39-year-old female with decompensated liver cirrhosis (Child-Pugh C) and acute variceal bleeding experienced a
Mahmoud Elshehawy, Richel Merin Panicker, Alaa Amr Abdelgawad, Patrick Anthony Ball, Hana Morrissey   +4 more
doaj   +3 more sources

Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome

New England Journal of Medicine, 2021
BACKGROUND The vasoconstrictor terlipressin is used for type 1 hepatorenal syndrome (HRS-1) in many parts of the world and is part of the clinical practice guidelines in Europe. METHODS We conducted a phase 3 trial to confirm the efficacy and safety of
Florence S H Wong, Michael Curry, K Rajender Reddy   +2 more
exaly   +2 more sources

Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome [PDF]

Clinical and Molecular Hepatology, 2013
Terlipressin is a vasopressin analogue that is widely used in the treatment of hepatorenal syndrome or variceal bleeding. Because it acts mainly on splanchnic vessels, terlipressin has a lower incidence of severe ischemic complications than does ...
Hae Rim Kim, Young Sun Lee, Hyung Joon Yim, Hyun Joo Lee, Ja Young Ryu, Hyun Jung Lee, Eileen L. Yoon, Sun Jae Lee, Jong Jin Hyun, Sung Woo Jung, Ja Seol Koo, Rok Sun Choung, Sang Woo Lee, Jai Hyun Choi   +13 more
doaj   +3 more sources

Practice guidance for the use of terlipressin for liver cirrhosis–related complications [PDF]

Therapeutic Advances in Gastroenterology, 2022
Background: Liver cirrhosis is a major global health burden worldwide due to its high risk of morbidity and mortality. Role of terlipressin for the management of liver cirrhosis–related complications has been recognized during recent years.
Xingshun Qi, Zhaohui Bai, Qiang Zhu, Gang Cheng, Yu Chen, Xiaowei Dang, Huiguo Ding, Juqiang Han, Lei Han, Yingli He, Fanpu Ji, Hongxu Jin, Bimin Li, Hongyu Li, Yiling Li, Zhiwei Li, Bang Liu, Fuquan Liu, Lei Liu, Su Lin, Dapeng Ma, Fanping Meng, Ruizhao Qi, Tianshu Ren, Lichun Shao, Shanhong Tang, Yufu Tang, Yue Teng, Chunhui Wang, Ran Wang, Yunhai Wu, Xiangbo Xu, Ling Yang, Jinqiu Yuan, Shanshan Yuan, Yida Yang, Qingchun Zhao, Wei Zhang, Yongping Yang, Xiaozhong Guo, Weifen Xie   +40 more
doaj   +2 more sources

The current applications and future directions of terlipressin [PDF]

Hepatol Commun
Terlipressin is a vasopressin analog with potent splanchnic vasoconstrictor properties. It has an established role in managing portal hypertensive bleeding and hepatorenal syndrome-acute kidney injury, with a growing body of evidence demonstrating ...
Dorothy Liu, Adam Testro, Avik Majumdar, Marie Sinclair   +3 more
semanticscholar   +2 more sources